Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RUBY
CUSIPN/A
Phone617-679-9600
Debt
Debt-to-Equity Ratio-0.28
Current Ratio12.27
Quick Ratio12.27
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees83
Outstanding Shares79,040,000
Market Cap$1.35 billion
Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions
What is Rubius Therapeutics' stock symbol?
Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."
How were Rubius Therapeutics' earnings last quarter?
Rubius Therapeutics Inc (NASDAQ:RUBY) announced its quarterly earnings data on Friday, August, 31st. The company reported ($3.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.60) by $2.73. During the same quarter last year, the business earned ($1.25) EPS. View Rubius Therapeutics' Earnings History.
When is Rubius Therapeutics' next earnings date?
What price target have analysts set for RUBY?
4 Wall Street analysts have issued 1-year target prices for Rubius Therapeutics' shares. Their predictions range from $37.00 to $40.00. On average, they expect Rubius Therapeutics' stock price to reach $38.50 in the next year. This suggests a possible upside of 123.6% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.
What is the consensus analysts' recommendation for Rubius Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.
Who are some of Rubius Therapeutics' key competitors?
Some companies that are related to Rubius Therapeutics include Ablynx (ABLYF), Aerie Pharmaceuticals (AERI), argenx (ARGX), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Regenxbio (RGNX), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT) and Solid Biosciences (SLDB).
Who are Rubius Therapeutics' key executives?
Rubius Therapeutics' management team includes the folowing people:
- Mr. David R. Epstein, Exec. Chairman (Age 56)
- Dr. Torben Lauesgaard Straight Nissen, Pres (Age 46)
- Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 62)
- Dr. Pablo J. Cagnoni, CEO & Director (Age 55)
- Dr. Avak Kahvejian, Co-Founder and Chief Innovation Officer
When did Rubius Therapeutics IPO?
(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.
When does Rubius Therapeutics' lock-up period expire?
Rubius Therapeutics' lock-up period expires on Monday, January 14th. Rubius Therapeutics had issued 10,483,000 shares in its public offering on July 18th. The total size of the offering was $241,109,000 based on an initial share price of $23.00. After the end of Rubius Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
How do I buy shares of Rubius Therapeutics?
Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rubius Therapeutics' stock price today?
One share of RUBY stock can currently be purchased for approximately $17.22.
How big of a company is Rubius Therapeutics?
Rubius Therapeutics has a market capitalization of $1.35 billion. Rubius Therapeutics employs 83 workers across the globe.
What is Rubius Therapeutics' official website?
How can I contact Rubius Therapeutics?
Rubius Therapeutics' mailing address is 325 VASSAR STREET SUITE 1A, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]
MarketBeat Community Rating for Rubius Therapeutics (NASDAQ RUBY)
MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote "Outperform" if you believe RUBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
